Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Operating Expenses (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Operating Expenses for 12 consecutive years, with $164.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 256.28% to $164.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $393.3 million through Dec 2025, up 160.63% year-over-year, with the annual reading at $393.3 million for FY2025, 160.63% up from the prior year.
  • Operating Expenses hit $164.7 million in Q4 2025 for Viking Therapeutics, up from $98.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $164.7 million in Q4 2025 to a low of $12.5 million in Q4 2021.
  • Historically, Operating Expenses has averaged $38.6 million across 5 years, with a median of $25.5 million in 2023.
  • Biggest five-year swings in Operating Expenses: increased 11.04% in 2021 and later soared 256.28% in 2025.
  • Year by year, Operating Expenses stood at $12.5 million in 2021, then skyrocketed by 62.13% to $20.3 million in 2022, then skyrocketed by 44.38% to $29.3 million in 2023, then soared by 57.89% to $46.2 million in 2024, then skyrocketed by 256.28% to $164.7 million in 2025.
  • Business Quant data shows Operating Expenses for VKTX at $164.7 million in Q4 2025, $98.6 million in Q3 2025, and $74.6 million in Q2 2025.